UPCC 19219: A Phase 1b/2 Open-label Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)
Recruiting
99 years or below
All
1 Location
Brief description of study
TBD
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
25 May 2021.
Study ID: 834571